Nano cap Kazia Therapeutics Limited (NASDAQ:KZIA) jumps 21% premarket on robust volume in reaction to Fast Track status in the U.S. for lead drug paxalisib for a type of brain cancer called glioblastoma.
Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.
Shares rallied in April when it reported positive preliminary data from a mid-stage study. Additional data should be available this year with final results expected in H1 2021.
Paxalisib, in-licensed from Roche in 2016, modulates an intracellular pathway called PI3K that plays a key role in cell growth, proliferation, survival and angiogenesis (growth of blood vessels).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.